NCT06655558

Brief Summary

The aging population is steadily increasing, partly due to increasing life expectancy. At the same time, chronic diseases, including those affecting the musculoskeletal system (e.g., osteoarthritis), whose prevalence increases with age, limit the daily activities of those affected and thus affect more and more people. Arthrosis is the most common form of these diseases worldwide. According to the l'Institut de la statistique du Québec, nearly one in two Quebecers aged 15 and over is affected by a chronic health problem. Knee orthosis is one form of treatment that helps patients suffering from knee gonarthrosis. This treatment aims to compensate for certain biomechanical deficits in patients. A variety of joint configurations exists to target specific biomechanical deficits. A constant challenge for companies manufacturing orthoses is transmitting the orthosis's biomechanical effect to the patient. The desired effect requires a change in the forces applied inside the knee, but the orthosis cannot directly transmit forces to the patient's bones due to its external nature to the body. Customization of orthoses is crucial to improve the transmission of the biomechanical effect as well as tolerance to it. O3D Inc. aims to validate the effectiveness of its new custom orthosis for treating knee gonarthrosis symptoms. Participants answered a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire before receiving their custom knee brace(Baseline) and after 8 weeks (56 days) of treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 31, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 21, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 23, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2025

Completed
3 months until next milestone

Results Posted

Study results publicly available

September 4, 2025

Completed
Last Updated

September 4, 2025

Status Verified

August 1, 2025

Enrollment Period

5 months

First QC Date

October 21, 2024

Results QC Date

August 7, 2025

Last Update Submit

August 31, 2025

Conditions

Keywords

knee orthosisknee bracevalidationWOMACknee painknee stiffnessdaily activitiesknee function

Outcome Measures

Primary Outcomes (4)

  • Change in WOMAC Total Score

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 24 item questionnaire about knee pain, stiffness and function. Each item uses a 5 point scale ranging from 0 (no pain, stiffness or difficulty) to 4 (extreme pain, stiffness or difficulty). Total score is the sum of all items and ranges from 0 to 96. Therefore low scores represent better knee health whereas high scores represent worse knee health. Change is calculated as : Change= Score after 8 weeks of treatment - Baseline Score

    At baseline and after 8 weeks of intervention(Day 56)

  • Change in WOMAC Pain Score

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subcore of 5 items about knee pain. Each item uses a 5 point scale ranging from 0 (no pain) to 4 (extreme pain). Pain score is the sum of all 5 items, ranges from 0 to 20. Therefore low scores represent better knee pain whereas high scores represent worse knee pain. Change is calculated as : Change= Score after 8 weeks of treatment - Baseline Score

    At baseline and after 8 weeks of intervention(Day 56)

  • Change in WOMAC Stiffness Score

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscore of 2 items about knee stiffness. Each item uses a 5 point scale ranging from 0 (no stiffness) to 4 (extreme stiffness). Stiffness score is the sum of 2 items, ranges from 0 to 8. Therefore low scores represent better knee stiffness whereas high scores represent worse knee stiffness. Change is calculated as : Change= Score after 8 weeks of treatment - Baseline Score

    At baseline and after 8 weeks of intervention(Day 56)

  • Change in WOMAC Physical Function Score

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscore of 17 items about knee function. Each item uses a 5 point scale ranging from 0 (no dificulty) to 4 (extreme dificulty). Functionnal limitation score is the sum of all 17 items, ranges from 0 to 68. Therefore low scores represent better knee function whereas high scores represent worse knee function. Change is calculated as : Change= Score after 8 weeks of treatment - Baseline Score

    At baseline and after 8 weeks of intervention(Day 56)

Study Arms (1)

medial gonarthrosis

EXPERIMENTAL

Patients with medial gonarthrosis

Device: custom knee orthosis

Interventions

The custom knee orthosis will be worn for 8 weeks (56 days).

medial gonarthrosis

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Suffering from medial gonarthrosis
  • Receiving a regular model of the O3D orthosis

You may not qualify if:

  • Suffering from tricompartmental gonarthosis
  • Having completed the delivery appointment for a O3D orthosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Topmed

Québec, G1S1C1, Canada

Location

Limitations and Caveats

Targeted enrollement of 30 participants was not reached. Interpretations should be taken with caution because of the small number of participants.

Results Point of Contact

Title
Edith Martin
Organization
Topmed

Study Officials

  • Edith Martin, Phd.

    TOPMED

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Longitudal treatment validation
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 21, 2024

First Posted

October 23, 2024

Study Start

July 31, 2024

Primary Completion

December 22, 2024

Study Completion

June 6, 2025

Last Updated

September 4, 2025

Results First Posted

September 4, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations